Atlas Trials

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Clinical trial NCT00045942 · COMPLETED

Trial details

NCT number
NCT00045942
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Start date
2002-01-30
Primary completion
2008-03-27
Enrollment
144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.